Sempra enters the week on a quietly positive note, with the stock up 2% on the week to $94.59 while every close peer drifted lower — and a fresh analyst initiation adding weight to the bull case.
The standout this week is on the Street. TD Cowen initiated coverage with a Buy rating on July 8, adding to an already constructive consensus of 12 buy ratings and a mean price target of $104.19 — roughly 10% above the current price. The broader analyst direction over recent months has been one of modest target trimming: Truist, BMO, and Morgan Stanley each nudged targets down by $1–$4 after the May print, while keeping positive ratings intact. That signals the Street still believes in the thesis but is calibrating its numbers more tightly to where the stock actually trades. Wells Fargo and JP Morgan, by contrast, raised targets earlier in the spring, reflecting confidence in the infrastructure buildout. The 12-month forward EPS growth factor ranks in the 76th percentile — the clearest quantitative support for the constructive bias. On valuation, Sempra trades at roughly 17.4x trailing earnings and 15.8x EV/EBITDA, both broadly stable over the past 30 days, suggesting the recent price recovery has kept pace with fundamentals rather than running ahead of them.
Positioning in the lending market is about as loose as it gets. Availability runs at over 5,000% — meaning there are roughly fifty lendable shares for every one currently borrowed — and the lending pool has widened further this week, up 12% from seven days ago. That removes any squeeze dynamic from the conversation entirely. Short interest is modest at 2.1% of the free float, and while it has climbed roughly 50% over the past month in share terms, the absolute level remains low enough that this reads more as a gradual rebuild from a very quiet base than any meaningful directional bet against the company. Borrowing costs have ticked up 26% on the week to 0.47%, but at that level the number is statistical noise — this is still one of the cheapest borrows in the utility sector. The ORTEX short score of 33.9 reflects that low-intensity picture; it has barely moved across the past ten sessions.
Options positioning has edged more defensive over the past two weeks. The put/call ratio is running at 0.63, above its 20-day average of 0.46 and about 1.2 standard deviations elevated, though well short of the 52-week high of 1.07. The move in the PCR has been gradual since mid-June, when the ratio sat below 0.20, pointing to a slow rotation toward hedging rather than any sudden risk-off shift. Given that Q2 earnings are scheduled for August 4, some of this positioning may reflect routine pre-earnings caution. Sempra's last three results each produced a negative one-day reaction — the most recent print in early May saw the stock fall 2.3% the day after the release, recovering only modestly over the following five sessions.
The peer divergence this week is worth noting. Closest correlates CMS, NI, and PEG each dropped between 0.8% and 1.4% on the week, while SRE added 2%. That outperformance likely reflects a combination of the TD Cowen initiation and the stock's California-Texas infrastructure positioning, which has drawn consistent institutional interest. JP Morgan Asset Management added 4.6 million shares in the quarter ended June 30, making it the most active institutional buyer among the top holders — a meaningful addition relative to its existing 15 million share position.
Insider flow is a mild negative in isolation but not alarming in context. Net insider activity across the past 90 days is technically positive in share terms, though the bulk of disclosed trades have been sells — including an EVP sale of roughly $724,000 in mid-June. Both buy transactions in the window were from independent directors, which carries less signal weight than C-suite purchases. The significance scores on all recent trades are low (2–3 out of 10), suggesting these are routine plan-driven transactions rather than conviction moves in either direction.
The next major focus for Sempra is the August 4 earnings release, where the pattern of modest post-result softness and the recently elevated put/call ratio will frame how investors interpret any guidance commentary on LNG project timelines and Oncor rate base growth.
See the live data behind this article on ORTEX.
Open SRE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
